1
|
Silva R, Ferreira D, Rodrigues LR. Exosome-based delivery of RNAi leads to breast cancer inhibition. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
2
|
Dastmalchi N, Azarbarzin S, Safaralizadeh R, Khojasteh SMB, Shadbad MA, Amini M, Baghbanzadeh A, Asl ER, Baghbani E, Lotfinejad P, Baradaran B. The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer. Med Oncol 2021; 39:9. [PMID: 34761351 DOI: 10.1007/s12032-021-01606-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Accepted: 10/27/2021] [Indexed: 10/19/2022]
Abstract
The deregulation of microRNAs (miRs) has been identified in tumor development. Indeed, the restoration of tumor-suppressive miRs has been associated with inhibited tumor development in various cancers. Herein, we aimed to evaluate the impact of combined miR-383-5p restoration, as a tumor-suppressive miR, with taxol therapy in suppressing MDA-MB-231 breast cancer development. MDA-MB-231 cell line was restored with miR-383-5p and treated with paclitaxel both in combined and separate manners. The MTT experiment was carried out to measure the cytotoxicity of the therapeutic approaches on the tumoral cells. Besides, flow cytometry was conducted to assess apoptosis and cell cycle status following the treatments. Furthermore, the expression levels of critical factors contributed to tumor proliferation, migration, apoptosis were investigated via the qRT-PCR and western blotting techniques. The outcomes pointed out that the miR-383-5p might substantially enhance the chemosensitivity of MDA-MB-231 to taxol. Besides, miR-383-5p restoration and the combined therapy of miR-383-5p restoration with paclitaxel could remarkably increase apoptosis, decrease cell viability, arrest the cell cycle, inhibit clonogenicity, suppress tumor migration, suppress the PI3K/Akt signaling pathway, and down-regulate PD-L1 expression of BC cells. The restoration of miR-383-5p can enhance the chemosensitivity of MDA-MB-231 cells to taxol. Despite the anti-tumoral effects of miR-383-5p restoration on MDA-MB-231 breast cancer development, the combined therapy of miR-383-5p restoration with paclitaxel can be more effective in repressing MDA-MB-231 breast cancer development.
Collapse
Affiliation(s)
- Narges Dastmalchi
- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, 5166616471, Tabriz, Iran
| | - Shirin Azarbarzin
- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, 5166616471, Tabriz, Iran
| | - Reza Safaralizadeh
- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, 5166616471, Tabriz, Iran.
| | | | - Mahdi Abdoli Shadbad
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.,Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731, Tabriz, Iran
| | - Mohammad Amini
- Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731, Tabriz, Iran
| | - Amir Baghbanzadeh
- Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731, Tabriz, Iran
| | - Elmira Roshani Asl
- Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731, Tabriz, Iran.,Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
| | - Elham Baghbani
- Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731, Tabriz, Iran
| | - Parisa Lotfinejad
- Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731, Tabriz, Iran
| | - Behzad Baradaran
- Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731, Tabriz, Iran.
| |
Collapse
|
3
|
Viana AFSC, Lopes MTP, Oliveira FTB, Nunes PIG, Santos VG, Braga AD, Silva ACA, Sousa DP, Viana DA, Rao VS, Oliveira RDCM, Santos FA. (-)-Myrtenol accelerates healing of acetic acid-induced gastric ulcers in rats and in human gastric adenocarcinoma cells. Eur J Pharmacol 2019; 854:139-148. [PMID: 30991046 DOI: 10.1016/j.ejphar.2019.04.025] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 03/02/2019] [Accepted: 04/11/2019] [Indexed: 02/07/2023]
Abstract
The gastroprotective property of (-)-myrtenol, a monoterpenoid, has been demonstrated previously against acute gastric ulceration induced by ethanol. However, the healing property of (-)-myrtenol in a chronic gastric ulcer model remains to be verified. This study evaluated its healing efficacy and the mechanism involved using the rat model of chronic gastric ulcer induced by serosal injection of 80% acetic acid in vivo, and human gastric adenocarcinoma cells (AGS) in vitro. The results showed that compared to vehicle-treated ulcer controls, oral administration of (-)-myrtenol (50 and 100 mg/kg/day) for 7 days promoted ulcer healing, as indicated by significant decreases in ulcer area and volume. The macroscopic and microscopic findings confirmed the healing potential of (-)-myrtenol. The ulcer healing activity was also associated with significant increases in gastric mucin content, collagen deposition, number of cells with positive marking for proliferating cell nuclear antigen (PCNA), and by changes in the expression of the inflammatory parameters tumor necrosis factor (TNF)-α, interleukin (IL)-1β and cyclooxygenase (COX)-2, as well as a decrease of metalloproteinases (MMP-9 and MMP-2) activity. Furthermore, in vitro assays using the AGS cultures revealed that (-)-myrtenol favors wound healing activity via stimulation of cell proliferation and migration without altering the cell viability. Taken together, these findings indicate that (-)-myrtenol has gastro-cytoprotective and ulcer healing properties that can be further explored to develop a new therapeutic agent from a natural source for the treatment of gastric ulcer.
Collapse
Affiliation(s)
- Ana Flavia S C Viana
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil; Medicinal Plants Research Center, Health Sciences Center, Federal University of Piauí, Teresina, Piauí, Brazil.
| | - Miriam Teresa P Lopes
- Department of Pharmacology, Laboratory of Antitumor Substances, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Francisca Tuelly B Oliveira
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil
| | - Paulo Iury G Nunes
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil
| | - Verlane G Santos
- Department of Pharmacology, Laboratory of Antitumor Substances, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Ariadne D Braga
- Department of Pharmacology, Laboratory of Antitumor Substances, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Ana Cândida A Silva
- Department of Pharmacology, Laboratory of Antitumor Substances, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Damião P Sousa
- Department of Pharmaceutical Sciences, Federal University of Paraiba, João Pessoa, Paraiba, Brazil
| | - Daniel A Viana
- Laboratory of Pathology and Legal Medicine, Faculty of Veterinary Science, State University of Ceará, Fortaleza, Ceará, Brazil
| | - Vietla S Rao
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil
| | - Rita de Cássia M Oliveira
- Medicinal Plants Research Center, Health Sciences Center, Federal University of Piauí, Teresina, Piauí, Brazil
| | - Flavia A Santos
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil
| |
Collapse
|
4
|
Qin L, Qiu H, Zhang M, Zhang F, Yang H, Yang L, Jia L, Qin K, Jia L, Dou X, Cheng L, Sang M, Zhang C, Shan B, Zhang Z. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment. Biomed Pharmacother 2016; 79:166-75. [PMID: 27044825 DOI: 10.1016/j.biopha.2016.01.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Revised: 12/18/2015] [Accepted: 01/13/2016] [Indexed: 11/16/2022] Open
Abstract
OBJECTIVE CD154 (CD40L) is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily of molecules. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. Being an activator of immune cells, CD40L has also been shown to directly induce apoptosis in tumor cells by multiple mechanisms. To understand the role of sCD40L in regulating the proliferation of epithelial ovarian cancer cells treated or untreated with cisplatin. METHODS Epithelial ovarian cancer cells: SKOV3 and its cisplatin-resistant strain SKOV3/DDP cells were used to test the effect of sCD40L and cisplatin. The proliferation of SKOV3 and SKOV3/DDP cells were measured by MTT. Cell cycle was assessed by flow cytometry. The mRNA expressions of targeted genes were detected by qRT-PCR. The protein expressions were detected by Western blotting. RESULTS sCD40L showed a significant dose-dependence inhibitory effect on the proliferation of ovarian cancer cell lines. sCD40L in combination with cisplatin could sensitized SKOV3/DDP cells to cisplatin treatment and reversed the drug resistance of SKOV3/DDP cells. The reversal ratios of 1 μg/ml sCD40L combined with cisplatin in SKOV3 and SKOV3/DDP cells were 2.11, 2.71, while the reversal ratios of 2 μg/ml sCD40L combined with cisplatin in SKOV3 and SKOV3/DDP cells were 3.78, 5.20, respectively. sCD40L or sCD40L combined cisplatin increased tumor cells in G0/G1 phase. sCD40L in combination with cisplatin decreased the expression levels of GST-π, LRP, Survivin, p53 and Bcl-2 in both epithelial ovarian cancer cell lines. The protein expression level of GST-π, LRP and P53 protein was also decreased upon sCD40L in combination with cisplatin although the expression level of Bcl-2 and survivin protein had no significant difference. CONCLUSION sCD40L inhibits the proliferation of SKOV3 and SKOV3/DDP cells. The combined application of sCD40L and cisplatin can strength the inhibitory effect of cisplatin, and to a certain extent, reversing the resistance to cisplatin in SKOV3/DDP cells. sCD40L could lead a cell block in G0/G1 phase and make the cell growth restrained. sCD40L could induce SKOV3 and SKOV3/DDP cells apoptosis and reverse drug resistance through cutting GST-π mRNA, LRP mRNA, survivin mRNA, p53 mRNA and Bcl-2 mRNA and decreasing the expression of GST-π, LRP and P53 protein in SKOV3 and SKOV3/DDP cells, which provides in-vivo experiment basis to the application of sCD40L as a drug improving ovarian cancer cells sensitivity to cisplatin.
Collapse
Affiliation(s)
- Lijun Qin
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Hongbing Qiu
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; Department of Gynecology and Obstetrics, XingTai People's Hospital Affiliated to Hebei Medical University, Xingtai 054000, China
| | - Minjie Zhang
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; Department of Gynecology and Obstetrics, Baoding Hospital for Women and Children's Health Care, Baoding 071000, China
| | - Fenghua Zhang
- Department of General Surgery, Hebei General Hospital, Shijiazhuang 050000, China
| | - Hongfang Yang
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Liu Yang
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Li Jia
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Kaiyun Qin
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Ling Jia
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Xiaomeng Dou
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Lili Cheng
- Department of Gynecology and Obstetrics, Zhaoxian County Hospital of Traditional Chinese Medicine, Shijiazhuang, 051530, China
| | - Meixiang Sang
- Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Chao Zhang
- Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - Baoen Shan
- Department of Gynecology and Obstetrics, Zhaoxian County Hospital of Traditional Chinese Medicine, Shijiazhuang, 051530, China
| | - Zhengmao Zhang
- Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
| |
Collapse
|